Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Sector Summary: The Healthcare sector (+0.9%) is trading higher today, in-line w/ the S&P 500 (+0.9%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>C.R. Bard (<strong>BCR</strong> +20.21%) to be acquired by Becton Dickinson and Co (BDX) for $317.00 per share</li><li>Akers Biosciences (<strong>AKER</strong> +8.06%) Aker Wellness app has been approved by the Apple App Store and is now available for download on iOS devices</li><li>Hooper Holmes (<strong>HH</strong> +4.58%) announces a new service contract with Paradigm Health Plans</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>XOMA (<strong>XOMA</strong> -10.74%) received notice from Novo Nordisk (NVO) of its termination of an exclusive license agreement due to strategic and business reasons</li><li>Eyegate Pharma (<strong>EYEG</strong> -7.65%) files for $11.5 mln common stock offering</li><li>Akari Therapeutics (<strong>AKTX</strong> -6.59%) presents positive response with coversin in ongoing phase 2 pnh trial and in additional clinical targets; interim Phase 2 PNH data demonstrate positive response with Coversin</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Motif Bio (<strong>MTFB</strong> +4.61%) Rodman & Renshaw Reiterated BUY — Price Target: 25 (from 16)</li><li>Mazor Robotics (<strong>MZOR</strong> -4.12%) downgraded to Equal Weight from Overweight at Barclays</li><li>Surgery Partners (<strong>SGRY</strong> -1.93%) Stifel Reiterated HOLD — Price Target: 18 (from 19)</li></ul></td> </tr></table>"